The Observational Study, led by the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the National Institutes of Health (NIH), aims to analyze the multifaceted causes of overweight and obesity in adults. While Novo Nordisk's (NVO) Wegovy and Eli Lilly's (LLY) Zepbound dominate the market, addressing patient-specific response variations and managing adverse effects remain key challenges. This study (NCT00428987), involving 2,000 participants, comprehensively collects genetic, metabolic, and behavioral data to provide a foundation for personalized treatment approaches. By comparing data with a control group, the study will elucidate the heterogeneous nature of obesity, serving as a crucial compass for developing next-generation targeted drugs.

The research team precisely evaluates insulin sensitivity and energy expenditure in obese patients through glucose tolerance tests and resting metabolic rate measurements. By tracking hormonal responses in the blood in real-time, the study aims to clarify the pathological connections with metabolic diseases and identify new incretin-based therapeutic targets. Furthermore, the concurrent analysis of adipose and muscle tissue biopsies to track changes in specific gene expression holds significant strategic value for biotechnology companies. This molecular-level dataset will facilitate the selection of more targeted clinical candidates and significantly reduce the risk of setbacks in early development.

The study integrates dietary preferences, sleep patterns, and neurocognitive function tests to precisely analyze the correlation between obesity and the brain's reward system. By quantifying cognitive function and the brain's response to food, the research aims to establish a clinical basis for next-generation combination therapies that integrate drug treatment with behavioral modification. This approach will enable a multifaceted analysis of the factors contributing to patients' failure to control their appetite, potentially leading to the development of combination drugs or the use of digital healthcare devices. It provides crucial insights for achieving sustained therapeutic effects by addressing obesity from a cognitive-behavioral perspective, going beyond mere physical appetite suppression.

Based on the large-scale biological samples collected from participants, the study systematically classifies internal genetic variations and gene expression patterns involved in weight regulation mechanisms. By elucidating the mechanisms by which specific genetic traits manifest as obesity phenotypes, the study ultimately aims to apply precision medicine to the field of obesity. This will enable pharmaceutical companies to develop targeted therapies for rare obesity conditions or companion diagnostics tailored to specific patient populations. This is expected to significantly increase the success rate of clinical trials and facilitate regulatory approvals.

The value of this fundamental scientific research data is immense, given that the global obesity treatment market is projected to grow to a maximum of $120 billion by 2030. While Novo Nordisk and Eli Lilly hold over 80% of the market share, this data can provide new targets and differentiation points for latecomers such as Amgen (AMGN) and Viking Therapeutics (VKTX). The NIDDK's long-term tracking database will serve as a valuable public research asset, verifying the safety of new drug pipelines and accelerating regulatory approvals.